- This study identifies a link between HbA1c level and the future development of dysglycaemia in cystic fibrosis (CF) based on oral glucose tolerance test (OGTT), as well as microvascular outcomes
Why this matters
- Although current guidance does not advocate the use of HbA1c as a diagnostic tool in cystic fibrosis-related diabetes (CFRD), it may be of clinical use in determining individuals at risk of future development of CFRD.
- This 7-year retrospective longitudinal study compared OGTT results with HbA1c measurements to predict CFRD risk in 50 adult patients with CF.
- Retinal screening data were compared with HbA1c measurements to evaluate microvascular outcomes.
- Funding: None.
- Of 50 patients with CF, 18 had HbA1c level of
- During the follow-up period, 4 patients with an HbA1c level of
- Patients with HbA1c level of ≥37 mmol/mol (5.5%) were significantly more likely to develop abnormal OGTT over a 7-year period (HR, 3.49; 95% CI, 1.5-8.1).
- Severe form of diabetic retinopathy was associated with higher HbA1c level (P=.038) and longer duration of CFRD risk (>5 years).
- Small population size.
- Study did not measure haematological variables.